Effects of PGI2 Analogue Use on the Development of Chronic Allograft Nephropathy

• Status: Completed
• Trial end date: 2014-06-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the effect of Prostaglandin I2 analogue use on the development of chronic allograft nephropathy and changes in allograft function in prevalent renal transplant recipients

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Seoul National University Hospital
• Treatments: Epoprostenol; Tezosentan

Criteria

Inclusion Criteria:

• prevalent renal transplant recipients 2 years after transplantation

• no history of acute rejection

• stable renal function

Exclusion Criteria:

• history of biopsy-proven chronic allograft nephropathy

• history of biopsy-proven CNI nephrotoxicity

• history of biopsy-proven or clinical acute rejection

• unstable trough level of CNI or extremely low level of CNI

• bleeding tendency(+)

• pregnancy or pregnant-willing

• anticoagulation(+)

• antiplatelet agent (+)

• significant comorbidity(+): Acute coronary syndrome, pneumonia